María-Victoria Mateos, Pawel Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Ward, P. Joy Ho, Roman Hajek, Kihyun Kim, Meletios Athanasios Dimopoulos, Claudio Cerchione, Nicholas Pirooz, Astrid McKeown, Chee Paul Lin, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Joanna Opalinska, Vania Hungria. "DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.7546